Instil Bio, Inc. Revenue
Instil Bio, Inc. (TIL) reported Revenue of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-07.
Discontinued
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2022-03-07
- Instil Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-12-31 was $0.00.
- Instil Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Instil Bio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $138.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-07 | $0.00 derived: sum of 3 quarters · filed 2022-03-07 | $0.00 10-K · filed 2022-03-07 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 4 quarters · filed 2022-03-07 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2022-03-07 | $52.00K derived: sum of 4 quarters · filed 2022-03-07 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | $0.00 derived: sum of 2 quarters · filed 2022-03-07 | $52.00K derived: sum of 3 quarters · filed 2022-03-07 | $94.00K derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $52.00K derived: sum of 2 quarters · filed 2022-03-07 | $94.00K derived: sum of 3 quarters · filed 2022-03-07 | $138.00K 10-K · filed 2022-03-07 |
| 2020-09-30 | $52.00K 10-Q · filed 2021-11-15 | $94.00K derived: sum of 2 quarters · filed 2021-11-15 | $138.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $42.00K 10-Q · filed 2021-08-12 | $87.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $44.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |